Would the 2nd battle break out between Trajenta and Januvia due to the beneficiary standard alteration?
While Trajenta (generic name: linagliptin) is catching up, Januvia (generic name: sitagliptin) is running away; the two products dividing the DDP-4 inhibitor market are reviving its endless chase using the alteration of the type II diabetes beneficiary standard as a trigger.
As joint uses of DDP...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
